Autres langues Orion Oyj

Actions

ORNBV

FI0009014377

Produits pharmaceutiques

Temps réel estimé Tradegate 10:28:40 06/10/2026			Varia. 5j.	Varia. 1 janv.
82,65 ^EUR	+2,23%		+0,18%	+29,69%

08:31	Orion va commercialiser en Europe le biosimilaire du pembrolizumab de Qilu Pharma	MT
05/10	Orion Corporation (Orion Pharma) annonce l’administration de la première dose dans l’essai clinique de phase 1/2 BICIDES évaluant ODM-216	CI

Autres langues

08:31	Orion to Commercialize Qilu Pharma's Pembrolizumab Biosimilar in Europe
08:00	Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market
05/10	Orion Corporation (Orion Pharma) Announces First Patient Dosed In BICIDES Phase 1/2 Clinical Trial Evaluating ODM-216
05/10	Orion Doses First Patient in Early-stage Trial of Potential Anticancer Drug
05/10	Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing
30/09	Orion Corporation completed share acquisitions
30/09	Orion Corporation: Acquisition of own shares during week 40, 2026
25/09	Orion Corporation: Acquisition of own shares during week 39, 2026
18/09	Orion Corporation: Acquisition of own shares during week 38, 2026
11/09	Orion Corporation: Acquisition of own shares during week 37, 2026
04/09	Orion Corporation: Acquisition of own shares during week 36, 2026
04/09	102,000 Orion Corporation A shares converted into B shares
04/09	Orion Oyj commences an Equity Buyback Plan for 500,000 shares, representing 0.46% of its issued share capital, under the authorization approved on March 24, 2026.
27/08	Orion Corporation to commence acquisition of own shares for its share-based incentive plans
10/08	Orion License Partner Tenax's Pulmonary Hypertension Drug Fails to Improve Walk Distance in Late-stage Trial
10/08	Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint
17/07	Orion Oyj Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
17/07	Orion Oyj Revises Earnings Guidance for the Full Year 2026
17/07	Orion Oyj : Half-Year Financial Report 2026
17/07	Orion Group Half-Year Financial Report January–June 2026
17/07	Orion Corporation’s financial reporting and Annual General Meeting in 2027
15/07	45,611 Orion Corporation A shares converted into B shares
06/07	Shilpa Biologicals Private Limited and Orion Corporation Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe
06/07	Orion publishes Half-Year Report for January-June 2026 and holds a webcast on 17 July 2026
03/07	Orion Oyj : publishes Half-Year Report for January-June 2026 and holds a webcast on 17 July 2026